Literature DB >> 12633545

Left ventricular remodelling and haemodynamic effects of multisite biventricular pacing in patients with left ventricular systolic dysfunction and activation disturbances in sinus rhythm: sub-study of the MUSTIC (Multisite Stimulationin Cardiomyopathies) trial.

A Duncan1, D Wait, D Gibson, J-C Daubert.   

Abstract

AIMS: To use echocardiography to determine early and late haemodynamic effects of atrio-biventricular (A-BiV) pacing on left ventricular (LV) function and their interrelations with exercise tolerance.
METHODS: Thirty-four patients with ejection fraction <35% (18 idiopathic dilated cardiomyopathy (DCM) and 16 ischaemic cardiomyopathy, in sinus rhythm and with intra-ventricular conduction delay (IVCD)) were implanted with transvenous A-BiV pacemakers. Echocardiographic measurements were compared before implantation, after 3 months A-BiV pacing, and 3 months inactive pacing (ventricular inhibited pacing at 40 beats x min(-1)as part of a crossover design, and at 9- and 12-month longitudinal follow-up.
RESULTS: Total isovolumic time (IVT) halved after 3 months A-BiV pacing (from 20.1+/-4.4 to 10.7+/-4.9s min(-1), P<0.001) and did not change thereafter. LV cavity size fell after 3 months (end-diastolic dimension (EDD) 7.3+/-0.8 to 6.8+/-0.8 cm, P<0.001, and end-systolic dimension (ESD) 6.2+/-0.8 to 5.9+/-0.8 cm, P<0.05), with a further fall in EDD and ESD (by 8.4+/-7.8 and 8.8+/-7.8mm, respectively, both P<0.001) after 12 months. Although not a primary end-point of the study, the 12-month reduction in LVEDD and LVESD was greater in idiopathic DCM (by 8.9 and 9.8mm, P<0.01, respectively) compared with ischaemic cardiomyopathy. The 6-min walk rose by 15% (P<0.01) and peak VO(2)by 10% (P<0.05) after 3 months, with no further increase by 12 months, and no difference between idiopathic DCM and ischaemic cardiomyopathy. The increase in peak VO(2)at 12 months correlated with the fall in ESD (r=0.47, P=0.03).
CONCLUSIONS: A-BiV pacing shortens total IVT, reduces LV cavity size, and increases exercise tolerance in patients with DCM and IVCD. Ischaemic cardiomyopathy does not affect the exercise response, although it does reduce the extent of reverse remodelling.

Entities:  

Mesh:

Year:  2003        PMID: 12633545     DOI: 10.1016/s0195-668x(02)00475-x

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  14 in total

Review 1.  Implantable cardioverter-defibrillator treatment and resynchronisation in heart failure.

Authors:  Cecilia Linde
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

2.  Cardiac resynchronisation therapy in chronic atrial fibrillation: impact on left atrial size and reversal to sinus rhythm.

Authors:  P Kiès; C Leclercq; G B Bleeker; C Crocq; S G Molhoek; C Poulain; L van Erven; M Bootsma; K Zeppenfeld; E E van der Wall; J-C Daubert; M J Schalij; J J Bax
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

3.  High-amplitude left ventricular pacing in cardiac resynchronization therapy: an alternative way to increase response rate in non-responders.

Authors:  Halit Zengin; Filiz Akın; Sabri Demircan; Korhan Soylu; Alirıza Erbay; Serkan Yuksel; Murat Meric; Okan Gulel; Mahmut Sahin; Ozcan Yılmaz
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

4.  Effect of cardiac resynchronization therapy on sleep quality, quality of life, and symptomatic depression in patients with chronic heart failure and Cheyne-Stokes respiration.

Authors:  Erik C Skobel; Anil-Martin Sinha; Christine Norra; Winfried Randerath; Ole-Alexander Breithardt; Christian Breuer; Peter Hanrath; Christoph Stellbrink
Journal:  Sleep Breath       Date:  2005-12       Impact factor: 2.816

5.  Exercise rehabilitation for chronic heart failure patients with cardiac device implants.

Authors:  Robert G Haennel
Journal:  Cardiopulm Phys Ther J       Date:  2012-09

6.  Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach.

Authors:  Daniel G Kramer; Thomas A Trikalinos; David M Kent; George V Antonopoulos; Marvin A Konstam; James E Udelson
Journal:  J Am Coll Cardiol       Date:  2010-07-27       Impact factor: 24.094

7.  Assessment of right ventricular oxidative metabolism by PET in patients with idiopathic dilated cardiomyopathy undergoing cardiac resynchronization therapy.

Authors:  Juhani Knuuti; Jan Sundell; Alexandru Naum; Erik Engblom; Juhani Koistinen; Antti Ylitalo; Kira Q Stolen; Riikka Kalliokoski; Stephan G Nekolla; K E Jeroen J Bax; K E Juhani Airaksinen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-29       Impact factor: 9.236

Review 8.  Recent advances in cardiac resynchronization therapy: echocardiographic modalities, patient selection, optimization, non-responders--all you need to know for more efficient CRT.

Authors:  Harry Pavlopoulos; Petros Nihoyannopoulos
Journal:  Int J Cardiovasc Imaging       Date:  2009-11-25       Impact factor: 2.357

Review 9.  Biventricular and novel pacing mechanisms in heart failure.

Authors:  Christina Salazar; William T Abraham
Journal:  Curr Heart Fail Rep       Date:  2009-03

10.  Long-term cardiac reverse remodeling after cardiac resynchronization therapy.

Authors:  Belén Alvarez-Alvarez; Javier García-Seara; Jose L Martínez-Sande; Moisés Rodríguez-Mañero; Xesús A Fernández López; Laila González-Melchor; Diego Iglesias-Alvarez; Francisco Gude; Carla Díaz-Louzao; José R González-Juanatey
Journal:  J Arrhythm       Date:  2021-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.